Search - tctmd.com

Displaying 221 - 240 of 352

Sort: Relevancy | Date

Presentation TCT 2014

Updates and Status of the ReCor Paradise Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Thomas Zeller

September 14, 2014

Presentation TCT 2014

Updates and Status of the St. Jude EnligHTN Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

Presentation TCT 2014

Updates and Status of the Boston Scientific Vessix Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Ajay J. Kirtane

September 14, 2014

Presentation TCT 2014

From SYMPLICITY HTN-1 to the Global SYMPLICITY Registry and Beyond: Updates from and Status of the SYMPLICITY Clinical Trial Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Michael Boehm

September 14, 2014

Presentation TCT 2014

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, John Flack

September 14, 2014

Presentation TCT 2014

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

News Conference News TCT 2014

PERFECT-LUTS: Endovascular Revascularization Shows Promise for Patients with ED, Lower Urinary Tract Symptoms

Yael L. Maxwell

September 14, 2014

$SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups$

Presentation TCT 2014

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

Presenter: Patrick W. Serruys, Deepak L. Bhatt

September 13, 2014

News Conference News TCT 2014

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

September 13, 2014

News Daily News

SCAAR: Menor Riesgo de Trombosis Precoz, Tardía del Stent con Nuevos SLF frente a SMD en el Manejo de Cuadros de STEMI

Yael L. Maxwell

July 03, 2014

News Daily News

SCAAR: Lower Risk of Early, Late Stent Thrombosis with Newer DES vs BMS in STEMI

Yael L. Maxwell

July 03, 2014

News Features

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

June 24, 2014

News Features

Denervación Renal 2.0: Marcando el Camino de la Recuperación Tras el Symplicity HTN-3

June 24, 2014

News Features

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

June 18, 2014

News Daily News

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

May 14, 2014

News Daily News

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

May 12, 2014

News Daily News

Renal Denervation Shows Promise in Patients Refractory to Stenting

L.A. McKeown

May 02, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Conference News ACC 2014

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Yael L. Maxwell

April 03, 2014

News Conference News ACC 2014

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

April 02, 2014

Advertisement

Updates and Status of the ReCor Paradise Program

Updates and Status of the St. Jude EnligHTN Program

Updates and Status of the Boston Scientific Vessix Program

From SYMPLICITY HTN-1 to the Global SYMPLICITY Registry and Beyond: Updates from and Status of the SYMPLICITY Clinical Trial Program

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

PERFECT-LUTS: Endovascular Revascularization Shows Promise for Patients with ED, Lower Urinary Tract Symptoms

SYMPLICITY HTN-3: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Refractory Hypertension: 12-Month Results in Subgroups

SYMPLICITY HTN-3: Crossover Patients Strengthen the Case for Renal Denervation

SCAAR: Menor Riesgo de Trombosis Precoz, Tardía del Stent con Nuevos SLF frente a SMD en el Manejo de Cuadros de STEMI

SCAAR: Lower Risk of Early, Late Stent Thrombosis with Newer DES vs BMS in STEMI

Renal Denervation 2.0: Laying Out the Road to Recovery from Symplicity HTN-3

Denervación Renal 2.0: Marcando el Camino de la Recuperación Tras el Symplicity HTN-3

Renal Denervation 2.0: Assessing the Failure of a Pivotal Trial

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

Many Patients Referred for Renal Denervation Improve with Medication Adjustment

Renal Denervation Shows Promise in Patients Refractory to Stenting

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

CHAMPION PHOENIX Analysis: Cangrelor Reduces Early Stent Thrombosis, Suggesting Mortality Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content